Revance Therapeutics | RVNC - Валовая прибыль



Валовая прибыль Изменить Дата
AbbVie USD 10.47B 605M 2025-09
ALKERMES USD 338.34M 72.51M 2025-12
Bristol-Myers Squibb USD 8.79B 110M 2025-09
Cara Therapeutics USD 2.57M 1.11M 2025-03
Coherus Biosciences USD 8.7M 853K 2025-12
Eli Lilly USD 14.59B 1.48B 2025-09
J&J USD 16.6B 118M 2025-12
Merck USD 13.42B 431M 2025-09
Neurocrine Biosciences USD 787.9M 7M 2025-12
P&G USD 11.37B 125M 2025-12
Pacira USD 142.25M 11.34M 2025-12
Supernus Pharmaceuticals USD 164.04M 15.23M 2025-12